Contineum Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
51
- Stock Symbol
-
CTNM
- Share Price
-
$9.88
- (As of Friday Closing)
Contineum Therapeutics General Information
Description
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Contact Information
Website
www.contineum-tx.comCorporate Office
- 3565 General Atomics Court
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 3565 General Atomics Court
- Suite 200
- San Diego, CA 92121
- United States
Contineum Therapeutics Stock Performance
As of 13-Nov-2026, Contineum Therapeutics’s stock price is $9.88. Its current market cap is $387M with 39.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.88 | $9.78 | $6.72 - $17.79 | $387M | 39.3M | 813K | -$1.77 |
Contineum Therapeutics Financials Summary
As of 30-Sep-2026, Contineum Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 274,899 | 240,618 | 164,345 | |
| Revenue | 0 | 0 | 0 | 50,000 |
| EBITDA | (72,297) | (67,901) | (50,905) | 18,967 |
| Net Income | (63,463) | (59,978) | (42,258) | 22,720 |
| Total Assets | 256,988 | 276,642 | 212,847 | 130,386 |
| Total Debt | 6,266 | 8,250 | 6,259 | 572 |
Contineum Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Contineum Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Contineum Therapeutics Comparisons
Industry
Financing
Details
Contineum Therapeutics Competitors (3)
One of Contineum Therapeutics’s 3 competitors is Ovid Therapeutics, a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ovid Therapeutics | Formerly VC-backed | New York, NY | ||||
| Oligomerix | Venture Capital-Backed | Bronx, NY | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA |
Contineum Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Contineum Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Contineum Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Contineum Therapeutics FAQs
-
When was Contineum Therapeutics founded?
Contineum Therapeutics was founded in 2017.
-
Where is Contineum Therapeutics headquartered?
Contineum Therapeutics is headquartered in San Diego, CA.
-
What is the size of Contineum Therapeutics?
Contineum Therapeutics has 51 total employees.
-
What industry is Contineum Therapeutics in?
Contineum Therapeutics’s primary industry is Drug Discovery.
-
Is Contineum Therapeutics a private or public company?
Contineum Therapeutics is a Public company.
-
What is Contineum Therapeutics’s stock symbol?
The ticker symbol for Contineum Therapeutics is CTNM.
-
What is the current stock price of Contineum Therapeutics?
As of 13-Nov-2026 the stock price of Contineum Therapeutics is $9.88.
-
What is the current market cap of Contineum Therapeutics?
The current market capitalization of Contineum Therapeutics is $387M.
-
Who are Contineum Therapeutics’s competitors?
Ovid Therapeutics, Oligomerix, and Neurona Therapeutics are competitors of Contineum Therapeutics.
-
What is Contineum Therapeutics’s annual earnings per share (EPS)?
Contineum Therapeutics’s EPS for 12 months was -$1.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
